RU2668373C1 - Композиции, содержащие аминокислоты для применения при лечении инсульта у пациентов с дисфагией - Google Patents

Композиции, содержащие аминокислоты для применения при лечении инсульта у пациентов с дисфагией Download PDF

Info

Publication number
RU2668373C1
RU2668373C1 RU2017112492A RU2017112492A RU2668373C1 RU 2668373 C1 RU2668373 C1 RU 2668373C1 RU 2017112492 A RU2017112492 A RU 2017112492A RU 2017112492 A RU2017112492 A RU 2017112492A RU 2668373 C1 RU2668373 C1 RU 2668373C1
Authority
RU
Russia
Prior art keywords
patients
stroke
amino acids
dysphagia
active substance
Prior art date
Application number
RU2017112492A
Other languages
English (en)
Russian (ru)
Inventor
Паоло Лука Мария ДЖОРДЖЕТТИ
Original Assignee
Профессьональ Дьететикс С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Профессьональ Дьететикс С.П.А. filed Critical Профессьональ Дьететикс С.П.А.
Application granted granted Critical
Publication of RU2668373C1 publication Critical patent/RU2668373C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2017112492A 2014-10-08 2015-10-07 Композиции, содержащие аминокислоты для применения при лечении инсульта у пациентов с дисфагией RU2668373C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITTO20140806 2014-10-08
ITTO2014A000806 2014-10-08
PCT/IB2015/057662 WO2016055948A1 (en) 2014-10-08 2015-10-07 Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia

Publications (1)

Publication Number Publication Date
RU2668373C1 true RU2668373C1 (ru) 2018-09-28

Family

ID=52101507

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017112492A RU2668373C1 (ru) 2014-10-08 2015-10-07 Композиции, содержащие аминокислоты для применения при лечении инсульта у пациентов с дисфагией

Country Status (14)

Country Link
US (1) US9707198B2 (enExample)
EP (1) EP3006027B1 (enExample)
JP (1) JP6447716B2 (enExample)
KR (1) KR102077374B1 (enExample)
AU (1) AU2015329581B2 (enExample)
CA (1) CA2958033C (enExample)
DK (1) DK3006027T3 (enExample)
ES (1) ES2651903T3 (enExample)
HU (1) HUE035699T2 (enExample)
NO (1) NO3006027T3 (enExample)
NZ (1) NZ728962A (enExample)
PL (1) PL3006027T3 (enExample)
RU (1) RU2668373C1 (enExample)
WO (1) WO2016055948A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016181335A1 (en) * 2015-05-14 2016-11-17 Professional Dietetics S.P.A. Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy
IT201700087376A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275084A1 (en) * 2009-07-15 2011-01-19 Unilever PLC Oral care composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US5276018A (en) * 1992-07-17 1994-01-04 Brigham And Women's Hospital Composition comprising amino acids and methods for decreasing muscle breakdown
IT1320783B1 (it) * 2000-07-04 2003-12-10 Professional Dietetics Srl Composizioni a base di aminoacidi, atte al miglioramento delleprestazioni muscolari.
US20030060421A1 (en) * 2001-07-19 2003-03-27 Neuron Therapeutics, Inc. Kits and compositions supporting intracranial perfusions
EP3231435A1 (en) * 2009-07-20 2017-10-18 Nestec S.A. Methods of attenuating the loss of functional status
BR112013022060B1 (pt) * 2011-03-01 2019-11-26 Nestec Sa produto nutricional, métodos para sua preparação e para melhorar sua coesão, e usos de um polímero de grau alimentício
JP2012214451A (ja) * 2011-03-25 2012-11-08 En Otsuka Pharmaceutical Co Ltd 炎症性疾患用アミノ酸組成物
JP5837315B2 (ja) * 2011-03-25 2015-12-24 イーエヌ大塚製薬株式会社 炎症性疾患用栄養組成物
WO2012133198A1 (ja) * 2011-03-25 2012-10-04 イーエヌ大塚製薬株式会社 炎症性疾患用栄養組成物
AU2012245002A1 (en) * 2011-04-21 2013-11-28 Fit-Bioceuticals Limited Weight loss composition
RU2526826C2 (ru) * 2012-10-24 2014-08-27 Николай Владимирович Соловьёв Композиция для парентерального введения, способ получения и применение композиции

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275084A1 (en) * 2009-07-15 2011-01-19 Unilever PLC Oral care composition

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AXEL G. FELLER. Nutrition Support in the Stroke Patient. Nutrition and Stroke, edited by Pierre Guesry, Michael Hennerici, and Gerhard Sitzer. Nestle Nutrition Workshop Series, Supplement. Nestec Ltd., Vevey/Lippincott-Raven Publishers, Philadelphia 1997 р.159-169 DISCUSSION р.170. *
DIOGUARDI F. S. Clinical use of amino acids as dietary supplement: pros and cons. Journal of Cachexia, Sarcopenia and Muscle, 2011vol. 2, no. 2, pp. 75-80, с. 78, фиг.1. *
DIOGUARDI F. S. Clinical use of amino acids as dietary supplement: pros and cons. Journal of Cachexia, Sarcopenia and Muscle, 2011vol. 2, no. 2, pp. 75-80, с. 78, фиг.1. AXEL G. FELLER. Nutrition Support in the Stroke Patient. Nutrition and Stroke, edited by Pierre Guesry, Michael Hennerici, and Gerhard Sitzer. Nestle Nutrition Workshop Series, Supplement. Nestec Ltd., Vevey/Lippincott-Raven Publishers, Philadelphia 1997 р.159-169 DISCUSSION р.170. WILFRED DRUML. Amino acid kinetics in patients with sepsis. Am J Clin Nutr 2001;73:908-13. Printed in USA. American Society for Clinical Nutrition 1-3. SHIN-JOE YEH. Dysphagia screening decreases pneumonia in acute stroke patients admitted to the stroke intensive care unit. Journal of the Neurological Sciences 306 (2011) 38-41 doi:10.1016/j.jns.2011.04.001. DIOGUARDI F. S. Clinical use of amino acids as dietary supplement: pros and cons. Journal of Cachexia, Sarcopenia and Muscle, 2011vol. 2, no. 2, pp. 75-80. *
DIOGUARDI F. S. Clinical use of amino acids as dietary supplement: pros and cons. Journal of Cachexia, Sarcopenia and Muscle, 2011vol. 2, no. 2, pp. 75-80. *
SHIN-JOE YEH. Dysphagia screening decreases pneumonia in acute stroke patients admitted to the stroke intensive care unit. Journal of the Neurological Sciences 306 (2011) 38-41 doi:10.1016/j.jns.2011.04.001. *
WILFRED DRUML. Amino acid kinetics in patients with sepsis. Am J Clin Nutr 2001;73:908-13. Printed in USA. American Society for Clinical Nutrition 1-3. *
РУМЯНЦЕВА С.А. Алгоритмы терапии острого инсульта. пункт 9. Новости медицины и фармации: всеукр. спец. мед.-фармац. изд. - Кихв. Неврология (328) 2010 (тематический номер) с.25-30. *

Also Published As

Publication number Publication date
KR20170057308A (ko) 2017-05-24
DK3006027T3 (en) 2017-12-18
US9707198B2 (en) 2017-07-18
CA2958033A1 (en) 2016-04-14
HUE035699T2 (en) 2018-05-28
ES2651903T3 (es) 2018-01-30
WO2016055948A1 (en) 2016-04-14
KR102077374B1 (ko) 2020-02-13
CA2958033C (en) 2019-07-16
JP2017530103A (ja) 2017-10-12
EP3006027B1 (en) 2017-11-15
NO3006027T3 (enExample) 2018-04-14
AU2015329581B2 (en) 2019-02-07
EP3006027A1 (en) 2016-04-13
NZ728962A (en) 2019-05-31
AU2015329581A1 (en) 2017-03-02
US20160101078A1 (en) 2016-04-14
PL3006027T3 (pl) 2018-02-28
JP6447716B2 (ja) 2019-01-09

Similar Documents

Publication Publication Date Title
Bo et al. A high whey protein, vitamin D and E supplement preserves muscle mass, strength, and quality of life in sarcopenic older adults: A double-blind randomized controlled trial
Viana et al. Impact of β− hydroxy-β− methylbutyrate (HMB) on muscle loss and protein metabolism in critically ill patients: A RCT
Ferrando et al. International Society of Sports Nutrition Position Stand: Effects of essential amino acid supplementation on exercise and performance
Bauer et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group
May et al. Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine, and glutamine
Symons et al. Aging does not impair the anabolic response to a protein-rich meal
Breen et al. Skeletal muscle protein metabolism in the elderly: Interventions to counteract the'anabolic resistance'of ageing
Børsheim et al. Essential amino acids and muscle protein recovery from resistance exercise
Irving et al. Effect of insulin sensitizer therapy on amino acids and their metabolites
Adachi et al. Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study
Rondanelli et al. Effect of essential amino acid supplementation on quality of life, amino acid profile and strength in institutionalized elderly patients
Aquilani et al. Unaffected arm muscle hypercatabolism in dysphagic subacute stroke patients: the effects of essential amino acid supplementation
RU2668373C1 (ru) Композиции, содержащие аминокислоты для применения при лечении инсульта у пациентов с дисфагией
Wicks et al. Sarcopenia, diabetes, and nutritional intervention
Cao et al. Intensive versus conventional insulin therapy in nondiabetic patients receiving parenteral nutrition after D2 gastrectomy for gastric cancer: a randomized controlled trial
Jirka et al. Effect of oral citrulline supplementation on whole body protein metabolism in adult patients with short bowel syndrome: A pilot, randomized, double-blind, cross-over study
US20230131476A1 (en) Compositions containing amino acids and methods of using such compositions for treating sarcopenia
Jourdan et al. O025 CITRULLINE STIMULATES MUSCLE PROTEIN SYNTHESIS AT THE POST-ABSORPTIVE STATE IN HEALTHY SUBJECTS FED A LOW-PROTEIN DIET
Takiguchi et al. Clinical trial of ghrelin synthesis administration for upper GI surgery
Ertuglu et al. Protein–Energy Wasting and Nutritional Interventions in Chronic Kidney Disease
JP7789007B2 (ja) アミノ酸を含有する組成物及びサルコペニアを治療するためにかかる組成物を使用する方法
Kawano et al. Successful treatment of heart failure in an adult patient with Prader-Willi syndrome
Deger et al. Nutritional Management of Hemodialysis Patients
Oyama et al. Jelly-type carbohydrate supplement in healthy subjects suppresses the catabolism of adipose tissue and muscle protein and improves their satisfactions
Lyon et al. 12 Metabolic Interventions for Sarcopenic Obesity